New paper out on cancer research priorities in resource-challenged regions post-COVID. Centering the voices of those that understand local issues:
https://t.co/YxKgXziZ7i
This is a stunning failure by the UK’s
public funders to continue to
support NCRI. No more joint planning, no more clinical study groups, etc. Following the demise of England cancer plan this is yet another colossal strategic failure @AggarwalOnc@WHO@UKIGlobalCancer
Great to see a packed series of sessions at #UKPROMs conference in Sheffield hosted by @ScHARRSheffield. Very happy to be representing @TOUR_KCL and @EORTC_QLG presenting our PROMs development work on immune checkpoint inhibitors
Really great job opportunities in the @CancerPrev_KCL to work on the BEST4 cytosponge project in the Cancer Prevention Trials Unit. A chance to make a real difference to early cancer diagnosis working with brilliant colleagues. https://t.co/wdrK0pTn5I
A pleasure to be part of this session at #WCC2022 with @MiekeVHR @dmukherji@SullivanProf. The challenge of the global cancer burden should be faced as a global community of equal partners - particularly amidst acute systemic pressures such as COVID and climate crises
The economic impacts of the COVID-19 pandemic alongside ongoing uncertainty regarding the virology and epidemiology of SARS-CoV-2 have implications for cancer research. A fascinating #WCC2022 session about redefining cancer research priorities in light of this.
Research shows #cancer patients are concerned about participating in research during the #COVID19 pandemic – with concerns disproportionately affecting women
Share your experiences as part of a follow-up study 👇
📧 [email protected]
Read more: https://t.co/FARsJbVGE2